Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer

Siddhartha Yadav, Chunling Hu, Steven N. Hart, Nicholas Boddicker, Eric C. Polley, Jie Na, Rohan Gnanaolivu, Kun Y. Lee, Tricia Lindstrom, Sebastian Armasu, Patrick Fitz-Gibbon, Karthik Ghosh, Daniela L. Stan, Sandhya Pruthi, Lonzetta Neal, Nicole Sandhu, Deborah J. Rhodes, Christine Klassen, Prema P. Peethambaram, Tufia C. HaddadJanet E. Olson, Tanya L. Hoskin, Matthew P. Goetz, Susan M. Domchek, Judy C. Boughey, Kathryn J. Ruddy, Fergus J. Couch

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


PURPOSE To determine the sensitivity and specificity of genetic testing criteria for the detection of germline pathogenic variants in women with breast cancer. MATERIALS AND METHODS Women with breast cancer enrolled in a breast cancer registry at a tertiary cancer center between 2000 and 2016 were evaluated for germline pathogenic variants in 9 breast cancer predisposition genes (ATM, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, and TP53). The performance of the National Comprehensive Cancer Network (NCCN) hereditary cancer testing criteria was evaluated relative to testing of all women as recommended by the American Society of Breast Surgeons. RESULTS Of 3,907 women, 1,872 (47.9%) meeting NCCN criteria were more likely to carry a pathogenic variant in 9 predisposition genes compared with women not meeting criteria (9.0% v 3.5%; P, .001). Of those not meeting criteria (n = 2,035), 14 (0.7%) had pathogenic variants in BRCA1 or BRCA2. The sensitivity of NCCN criteria was 70% for 9 predisposition genes and 87% for BRCA1 and BRCA2, with a specificity of 53%. Expansion of the NCCN criteria to include all women diagnosed with breast cancer at # 65 years of age achieved . 90% sensitivity for the 9 predisposition genes and . 98% sensitivity for BRCA1 and BRCA2. CONCLUSION A substantial proportion of women with breast cancer carrying germline pathogenic variants in predisposition genes do not qualify for testing by NCCN criteria. Expansion of NCCN criteria to include all women diagnosed at # 65 years of age improves the sensitivity of the selection criteria without requiring testing of all women with breast cancer.

Original languageEnglish (US)
Pages (from-to)1409-1418
Number of pages10
JournalJournal of Clinical Oncology
Issue number13
StatePublished - May 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer'. Together they form a unique fingerprint.

Cite this